Role of biomarkers of collagen metabolism and systemic inflammation in myocardial remodeling in patients with stable chronic coronary artery disease and obstructive sleep apnea
https://doi.org/10.15829/1728-8800-2023-3819
EDN: FPMMDJ
Abstract
Aim. To study the relationship of biomarkers of collagen metabolism and systemic inflammation with left ventricular (LV) remodeling in patients with stable coronary artery disease (CAD) and obstructive sleep apnea (OSA).
Material and methods. The study included 195 patients with stable CAD, of which 63 without OSA and 132 patients with combination of CAD and OSA. The mean age of patients was 63,4±3,7 years. Biomarkers of collagen metabolism and systemic inflammation were assessed by determining the concentration of matrix metalloproteinase (MMP)-9, tissue inhibitor of matrix metalloproteinase-1, monocyte chemoattractant protein-1 (MCP-1) and calculating the neutrophil-to-lymphocyte (NLR) and platelet-tolymphocyte ratio (PLR). Echocardiography was performed according to a standard protocol.
Results. There were no significant differences in systemic inflammation parameters (MCP-1, NLR, PLR) between the group of patients with CAD and CAD with mild OSA and a significantly higher level of MCP-1, NLR, PLR in more severe OSA. In patients with CAD and severe OSA, the eccentric LV remodeling was diagnosed in 75% of individuals, while the concentric type was diagnosed in only 25%.
Conclusion. In patients with stable CAD, the more severe the OSA, the more pronounced systemic inflammation (MCP-1, NLR, PLR), and there are higher proportion of eccentric LV hypertrophy, which may be associated with an imbalance of fibrosis markers (high concentration of MMP-9 with an almost unchanged level of tissue inhibitor of MMP-1).
About the Authors
O. A. OsipovaRussian Federation
Belgorod, Moscow
E. V. Gosteva
Russian Federation
Belgorod, Voronezh
T. A. Petrichko
Russian Federation
Khabarovsk
T. N. Ponomarenko
Russian Federation
Belgorod
V. V. Bukatov
Russian Federation
Belgorod
R. N. Shepel
Russian Federation
Moscow
L. V. Vasilyeva
Russian Federation
Voronezh
A. A. Kryshka
Russian Federation
Belgorod
A. V. Serdyukova
Russian Federation
Belgorod
A. S. Brizhaneva
Russian Federation
Belgorod
References
1. Smelov PA, Nikitina SY, Ageeva LI, et al. Zdravookhranenie v Rossii. 2021: Stat.sb./Rosstat. M., 2021. 171 р. (In Russ.)
2. Sviryaev YuV, Korostovtseva LS, Zvartau NE, et al. Prognostic value of obstructive sleep apnea syndrome: intermediate results of a five-year prospective observation. Arterial Hypertension. 2011;17(1):10-6. (In Russ.) doi:10.18705/1607-419X-2011-1.
3. Agaltsov MV, Drapkina OM. Relation of obstructive sleep apnea and cardiovascular diseases from the perspective of evidence-based medicine. Part 1. Cardiovascular Therapy and Prevention. 2020;19(3):2405. (In Russ.) doi:10.15829/1728-8800-2020-2405.
4. Larina VN, Mironova TN, Yelfimova EM, et al. Possibility of early detection of obstructive sleep breathing disorders at the outpatient stage. Cardiovascular Therapy and Prevention. 2018;17(3):38-45. (In Russ.) doi:10.15829/1728-8800-20183-38-45.
5. Yakovlev AV, Efremov IA, Ryabikov AN, et al. Prognostic value of echocardiographic parameters of cardiac remodeling in patients with arterial hypertension and obstructive sleep apnea syndrome. Arterial Hypertension. 2023;29(2):164-74. (In Russ.) doi:10.18705/1607-419X-2023-29-2-164-174.
6. Medvedeva EA, Korostovtseva LS, Sazonova YV, et al. Obstructive sleep apnea syndrome in chronic heart failure: a cardiologist’s view. Russian Journal of Cardiology. 2018;(1):78-82. (In Russ.) doi:10.15829/15604071-2018-1-78-82.
7. Brodovskaya TO, Grishchenko OO, Grishina IF, Peretolchina TF. Features of cardiac remodeling in patients with obstructive sleep apnea syndrome and its comorbid association with obesity in the context of the concept of early aging. Russian Journal of Cardiology. 2019;(4):27-34. (In Russ.) doi:10.15829/1560-4071-2019-4-27-34.
8. Grakova EV, Yakovlev AV, Shilov SN, et al. Heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome: prognostic value of biomarkers. Kardiologiia. 2021;61(11):77-88. (In Russ.) doi:10.18087/cardio.2021.11.n1615.
9. Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B): 107598. doi:10.1016/j.intimp.2021.107598.
10. Traxdorf M, Haferkamp J, Messbacher ME, et al. TIMP-1 as a biomarker in obstructive sleep apnea: screening, monitoring, risk stratification, and a step towards precision medicine. European review for medical and pharmacological sciences. 2023;27(4):1374-83. doi.10.26355/eurrev_202302_31374.
11. Wang S, Li S, Wang B, et al. Matrix metalloproteinase-9 is a predictive factor for systematic hypertension and heart dysfunction in patients with obstructive sleep apnea syndrome BioMed Res Int. 2018;2018:1569701. doi:10.1155/2018/1569701.
12. Osipova OA, Gosteva EV, Chefranova ZhY, et al. Effect of pharmacotherapy on the dynamics of markers of collagen metabolism in patients with chronic heart failure with intermediate ejection fraction on the background of ischemic heart disease in older age groups. Cardiovascular Therapy and Prevention. 2020;19(5):2651. (In Russ.) doi:10.15829/1728-8800-2020-2651.
13. Osipova OA, Gosteva EV, Golivets TP, et al. Dynamics of myocardial fibrosis markers in the use of beta-adrenoblockers and mineralocorticoid receptor antagonist in patients with chronic heart failure with intermediate ejection fraction of ischemic genesis. Cardiovascular Therapy and Prevention. 2021;20(7):3068. (In Russ.) doi:10.15829/1728-88002021-3068.
14. Polunina OS, Aksenov AI. Significance of the system of matrix proteins and their inhibitors in genesis of cardiovascular pathology and myocardial remodeling. Astrakhan Medical Journal. 2016;11(2):42-57. (In Russ.)
15. Peker Y, Akdeniz B, Altay S, et al. Obstructive sleep apnea and cardiovascular diseases: where are we? Anatol J Cardiol. 2023;27(7):375-89. doi:10.14744/AnatolJCardiol.2023.3307.
16. Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/1560-4071-2020-4076.2020.
17. Buzunov RV, Palman AD, Melnikov AYu, et al. Diagnostics and Treatment of Obstructive Sleep Apnea Syndrome in Adults. Recommendations of the Russian Society of Sleep Medicine. Effektivnaya farmakoterapiya. 2018;(35):34-45. (In Russ.)
18. Nadeem R, Molnar J, Madbouly EM, et al. Serum inflammatory markers in obstructive sleep apnea: A meta-analysis. J Clin Sleep Med. 2013;9:1003-12. doi:10.5664/jcsm.3070.
19. Kong D, Qin Z, Wang W, Kang J. Effect of obstructive sleep apnea on carotid artery intima media thickness related to inflammation. Clin. Invest. Med. 2017;40:E25-33. doi:10.25011/cim.v40i1.28051.
20. Perrini S, Cignarelli A, Quaranta VN, et al. Correction of intermittent hypoxia reduces inflammation in obese subjects with obstructive sleep apnea. JCI Insight. 2017;2:17. doi:10.1172/jci.insight.94379.
21. Silva WA, Almeida-Pititto B, Santos RB, et al. Obstructive sleep apnea is associated with lower adiponectin and higher cholesterol levels independently of traditional factors and other sleep disorders in middle-aged adults: The ELSA-Brasil cohort. Sleep Breath. 2021;25:1935-44. doi:10.1007/s11325-021-02290-7.
22. Imani MM, Sadeghi M, Mohammadi M, et al. Association of Blood MCP-1 Levels with Risk of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. Medicina (Kaunas, Lithuania). 2022;58(9):1266. doi:10.3390/medicina58091266.
23. Osipova OA, Gosteva EV, Zhernakova NI, et al. 24-hour blood pressure profile and systemic inflammation in patients with stable coronary artery disease with obstructive sleep apnea. Cardiovascular Therapy and Prevention. 2023;22(9):3705. (In Russ.) doi:10.15829/1728-8800-2023-3705.
24. Mashaqi S, Mansour HM, Alameddin H. Matrix metalloproteinase-9 as a messenger in the cross talk between obstructive sleep apnea and comorbid systemic hypertension, cardiac remodeling, and ischemic stroke: a literature review. J Clin Sleep Med. 2021;17(3):567-91. doi:10.5664/jcsm.8928.
25. Aksenov AI, Polunina OS, Myasoedova EI. Matrix metalloproteinases and their tissue inhibitors of patients with chronic ischemia disease. Transbaikalian Medical Bulletin. 2016;(4): 64-9. (In Russ.)
26. Yafarova AA, Kiselev AR, Sheptulina AF, Drapkina OM. Modern ideas about the role of galaninergic system in the pathogenesis of heart failure and myocardial remodeling. Cardiovascular Therapy and Prevention. 2023;22(5):3546. (In Russ.) doi:10.15829/1728-8800-2023-3546.
27. Chami HA, Devereux RB, Gottdiener JS, et al. Left ventricular morphology and systolic function in sleep disordered breathing: the Sleep Heart Health Study. Circulation. 2008;117:2599-607. doi:10.1161/CIRCULATIONAHA.107.717892.
28. Yamagushi T, Takata Y, Usui Y, et al. Noctural Intermittent Hypertension and Obstructive Sleep Apnea. Am J Hypertension. 2016;29:372-8. doi:10.1093/ajh/hpv115.
Supplementary files
What is already known about the subject?
- Obstructive sleep apnea (OSA) is the most common sleep-disordered breathing type, results in reduced or absent airflow and influences the severity of cardiovascular disease.
- In OSA, intermittent hypoxia leads to increased levels of circulating inflammatory markers.
What might this study add?
- In patients with stable coronary artery disease and OSA, the severity of systemic inflammation is higher with more severe OSA.
- An imbalance in matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio in patients with coronary artery disease and OSA is reflected in an increase in the number of patients with an eccentric left ventricular remodeling.
Review
For citations:
Osipova O.A., Gosteva E.V., Petrichko T.A., Ponomarenko T.N., Bukatov V.V., Shepel R.N., Vasilyeva L.V., Kryshka A.A., Serdyukova A.V., Brizhaneva A.S. Role of biomarkers of collagen metabolism and systemic inflammation in myocardial remodeling in patients with stable chronic coronary artery disease and obstructive sleep apnea. Cardiovascular Therapy and Prevention. 2023;22(12):3819. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3819. EDN: FPMMDJ